Αρχική World News FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway Modulation-Naïve... World News FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer Από Ogkologos - 15 Ιουλίου, 2026 262 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR No OS Benefit in EGFR T790M Advanced NSCLC Treated with Osimertinib... 2 Σεπτεμβρίου, 2020 Η ΚΑΘΗΜΕΡΙΝΟΤΗΤΑ 10 Δεκεμβρίου, 2018 Oligoprogression in Metastatic NSCLC Could Be Effectively Treated with SBRT Plus... 21 Δεκεμβρίου, 2023 EMA Recommends Granting a Conditional Marketing Authorisation for Ciltacabtagene Autoleucel 22 Απριλίου, 2022 Φόρτωση περισσοτέρων HOT NEWS Husband Turns Wife’s Inspiring Poem for Her Daughters into a Book... Taking on DNA repair to tackle cancer Her Mother Died of Breast Cancer When She Was Five. 16... Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers